Date	Presenter	Title	Journal	Year	Vol	Page
2024/9/3	宮﨑	Regulation of the hematopoietic stem cell pool by C-Kit-associated trogocytosis	Science	2024	385(6709)	eadp2065
10/8	鳥山	Pathological landscape of tumor flare reaction to epcoritamab treatment	Int J Hematol	2024	120(4)	467-471
		Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma	Cancer Sci	2023	114(12)	4643-4653
		Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma	J Hematol Oncol	2024	17(1):69	69
	加藤	Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma	Blood	2024	144(9)	955-963
11/12	山田	Ascirninib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia	Blood	2024	2024025800	doi: 10.1182/blood.2024025800.
		Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma	NEJM	2024	391(15)	:1379-1389
	安東	Coordinated inheritance of extrachromosomal DNAs in cancer cells	Nature	2024	635(8037)	201-209
11/19	佐藤	How I Treat patients with AML using azacitidine and venetoclax	Blood	2024	2024024009	doi: 10.1182/blood.2024024009
	坂本	Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy	NEJM	2024	391(14)	1287-1301
11/26	桐野	Clinical Features and Prognosis of Patients with COVID-19 and B-Cell Non-Hodgkin Lymphoma	Infect Drug Resist	2024	17	4501-4510
		Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study	Lancet Haematol	2020	7(10)	e737-e745
		Early combination therapy of COVID-19 in high-risk patients	Infection	2024	52(3)	877-889
	田口	Clonal dynamics after allogeneic haematopoietic cell transplantation	Nature	2024	635(8040)	926-934
12/3	宮﨑	Real-world impact of fuspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study	Leuk Res	2024	148	107624
		Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial	Lancet	2023	402(10399)	373-385
		Treatment patterns and outcomes with luspatercept in patients with lower-risk myelodysplastic syndromes: A retrospective US cohort analysis	Hemasphere	2024	8(1)	e38
		A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes	Int J Hematol	2024		doi: 10.1007/s12185-024-03872-3.
	鳥山	Therapy-related core binding factor acute myeloid leukemi	Int J Hematol Oncol	2023	12(1)	IJH43
12/10	児嶋	Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine	Blood	2024	144(21)	2211-2222

-						
	山田	Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation	Blood	2024	143(11)	953-966
2025/1/7	南野	Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort study	Blood Adv	2025	9(4)	893-905
		A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma	Eur J Cancer	2024	196	113436
		CNS relapse in high-grade B-cell lymphoma with MYC and BCL2 rearrangements and dark-zone signature-expressing DLBCL	Blood	2025	145(6)	590-596
-	安東	In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy	Cancer cell	2024	42(11)	955-1969
1/14	糸永	Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm	Blood	2024	144(19)	1987-1992
		Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations	Haematologica	2025	110(1):22-36	22-36
		Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee	Blood	2024	143(22)	2227-2244
		Highly efficient and rapid generation of human pluripotent stem cells by chemical reprogramming	Cell Stem Cell	2023	30(4)	450-459.e9
		Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient	Cell	2024	187(22)	6152-6164.e18
-	佐藤	Germ line ERG haploinsufficiency defines a new syndrome with cytopenia and hematological malignancy predisposition	Blood	2024	144(17)	1765-1780
1/21	坂本	Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial	Nat Med	2024	30(8)	2277-2287
		Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation	Blood	2024	144(17)	1834-1845
		Salvage Autologous Transplant in Relapsed Multiple Myeloma: Long-Term Follow-Up of the Phase 3 GMMG ReLApsE Trial	Blood	2025		blood.2024027342
-	学生	Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma	NEJM	2024		doi: 10.1056/NEJMoa2409029
1/28	桐野	Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML	Blood adv	2025	9(2)	375-385
	田口	The present and future of measurable residual disease testing in acute myeloid leukemia	Haematologica	2022	107(12)	2810-2822
		Principles of digital sequencing using unique molecular identifiers	Mol Aspects Med	2024	96	101253
2/18	学生	Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults	NEJM	2024	391(4)	320-333
	鳥山	Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)	J Clin Oncol	2025	43(1)	75-84
3/4	宮﨑	The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001	Radiat Res	2013	179(3)	361-82
		Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors	J Clin Oncol	2011	1;29(4)	428-34
3/11	勝岡	CPX-351+/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study	Br J Haematol	2025	206(2)	551-555
		Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease	Bone Marrow Transplant	2025	60(1)	69-78

1						
4/1	山田	The ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma	Blood	2025	145(11)	1164-1181
	安東	Loe-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients	Cancer cell	2025	43(3)	361-379
		Clonal Hematopoiesis Land scape in Frequent Blood Donors	Blood	2025		doi: 10.1182/blood.2024027999.
		α-Ketoglutarate dehydrogenase is a therapuetic vulnerability in acute myeloid leukemia	Blood	2025	145(13)	1422-1436
4/8	南野	Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high risk myelodisplastic syndromes.	Blood	2025	145(11)	1126-1135.
	佐藤	Prognostic biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of alliance studies	Leukemia	2025	39(3)	623-631
		Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia	Blood advance	2023	7(24)	7576-7580.
		Venetoclax and decitabine versus intensive chemotherapy as induction in young patients with diagnosed acute myeloid leukemia (AML)	Blood	2025		doi: 10.1182/blood.2024027217.
4/15	桐野	Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Flontline Setting Among Older Adults With Chronic Lymphocytic Leukemia	JCO Oncol Pract	2024		doi: 10.1200/OP.24.00220.
		Acquired mutations in patients with relpased/refractory CLL who progressed in the ALPINE study	Blood Adv	2025	9(8)	1918-1926.
4/22	児嶋	Triple-Negative Myelofibrosis Disease Features, Response to Treatment and Outcomes	Clin Lymphoma Myeloma Leuk	2025	24(7)	459-467.
	蓬莱	A phase I trial of pizloncabtagene autoleucel, a CD19/CD20 CART-cell therapy for relapsed/refractory B-cell non Hodgkin lymphoma	Blood	2025	145(14)	1526-1535.
5/13	糸永	Mitocondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis	Nature	2025		doi: 10.1038/s41586-025-08980-6.
5/20	宮﨑	Tumor-infiltrating Clonal Hematopoiesis	NEJM	2025	392(16)	1594-1608
5/27	坂本	Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in MIce and Humans after Hematopietic Cell Transplantations	Cancer Discov	2025	15(4)	748-766
	加藤	Development of patient-derived lymphomoids with preserved tumor architecture for lymphoma therapy screening	Nat Commun	2025	15(1)	10650
		Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma	Nat Commun.	2025	16	109
6/3	小谷	Iburutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study	Lancet Oncol	2025	26(2)	200-213.
	山田	Emerging biomarker for CD3xCD20 bispecific antibodies in lymphoma	Blood	2025	145(17)	1850-1857.
	山田	Ibntegrative genomic analysis of DLBCL indentifires immune environments associates with bispecific antibody response	Blood	2025	145(21)	2460-2472.
6/17	宇佐	Mosunetuzumab plus pola—CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study	Blood	205	9(10)	
		subgroup analysis of older patients ≧60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study	Blood adv	2025	9(10)	
		Real-world effectiveness and safety of rituximab and reduced- dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-call lymphoma: aretrospective analysis	Blood Res	2025	60(1)	
	クリクラ	Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma	BBlood	2025	145(9):	944-955.

6/24	鳥山	Measurable residual disease-guided therapy for chronic lymphocytic leukemia	NEJM	2025		doi: 10.1056/NEJMoa2504341.
	西村	A belt-and suspenders approach to PNH	Blood	2025	145(8)	785-786
		$Long-term\ efficacy\ of\ danicopan\ as\ add-on\ the rapy\ to\ ravulizumab\ or\ eculizumab\ in\ PNH\ with\ significant\ EVH$	Blod	2025	145(8)	811-822
		Oral I ptacopan Monotherapy in Paroxysmal Noctumal Hemoglobinuria	NEJM	2024	390(11)	994-1008.
7/1	勝岡	miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape	nature communication	2025	16(1)	1253
	澤	chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management	AJH	2024	99(7)	1360-1387
		sever bleeding tendency caused by leukemic infiltration and destruction of vascular walls in chronic neutrophil leukemia	Internal journal of hematology	2001	74(4)	437-41.
		A CSF3RT618I mutation in a patient with chronic neutrophilic leukemia and severe bleeding complications	Internal medicine	2016	55(4)	405-7
7/8	佐藤	Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial	nature medicine	2025	31(5)	1531-1538
	安東	Mis-splicing -derived neoantigens and cognate TCRs in splicing factor mutant leukemias	cell	2025	188(13)	3422-3440
		Tumor-wide RNA splicing aberrations generate actionable public neoantigens	nature	2025	639(8054)	463-473.
7/15	学生(クリクラ)	Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study	Blood	2025	145(24)	2914-2926
	蓬莱	An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma	nature medicine	2025	31(4)	1183-1194
		Allogeneic chimeric Antigen Receptor T-cell products cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-cell Lymphoma: phase 1 experience from the ALPHA2/ALPHA clinical studies	J Clin Oncol	205	10;43(14)	1695-1705.
7/22	児嶋	$Blood-based\ proteomic\ profiling\ identifies\ OSMR\ as\ a\ novel\ biomarker\ of\ AML\ outcomes$	Blood	2025	145(25)	3015-3029.
	糸永	CAR-T総論				
		Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin	NEJM	2025	393(3)	243-254